Bispecific Antibody Preclinical Licensing Benchmarks
Deal economics across 21 transactions with 16 disclosed upfront payments. Primary-source-verified from SEC EDGAR, FTC filings, and direct research.
Median Upfront
$62M
16 deals with terms
Median Total Value
$850M
Upfront + milestones
Royalty Range
5.8%--12.3%
Average low--high
Deal Count
21
2018--2026
The median upfront payment for preclinical bispecific antibody licensing deals is $62M, based on 16 deals with disclosed terms from 2018--2026. Total deal values (including milestones) reach a median of $850M. Royalty rates typically range from 5.8% to 12.3%. All data is primary-source-verified from SEC EDGAR, FTC pre-merger filings, and company press releases.
Representative Transactions
| Licensor | Licensee | Year | Upfront | Total Value |
|---|---|---|---|---|
| Numab Therapeutics | Johnson & Johnson | 2024 | $1.3B | $1.3B |
| Proteologix | Johnson & Johnson | 2024 | $850M | $850M |
| Vir Biotechnology | Astellas Pharma | 2025 | $335M | -- |
Showing 3 of 16 deals with disclosed terms. Full comp set available in the report.
Full Bispecific Antibody Preclinical Comp Set
Get the complete analysis -- 16 deals with upfronts, milestones, royalties, and term structures.
Primary-source-verified from SEC EDGAR, FTC filings, and direct research
Run Your Own Analysis
Get a customized deal estimate for your specific bispecific antibody asset with our proprietary calculator.
Start CalculatingMethodology
This analysis draws from the Ambrosia Ventures proprietary deal database (1,600+ verified biopharma transactions, 2018--2026). All deal terms are primary-source-verified from SEC EDGAR (10-K, 10-Q, 8-K filings), FTC pre-merger notifications, FDA Orange Book, and company press releases. No secondary-source or scraped data is included. Medians are calculated from deals with disclosed financial terms only.